Loading...
We have set up our new Discord server! Share your feedback and find like-minded people! Join our Discord
- Ticker
- CYAD
- Price
- -
- Stock movement down
- -0.03 (-5.42%)
- Company name
- Celyad SA
- Exchange
- (NASDAQ ,
- Currency
- USD )
- Sector
- Healthcare >Biotechnology & Medical Research
- Market cap
- 11.84M
- Ent value
- -331.74K
- Price/Sales
- -
- Price/Book
- 0.61
- Div yield
- -
- Div growth
- -
- Growth years
- -
- FCF payout
- -
- Trailing P/E
- 80.00
- Forward P/E
- -
- PEG
- -
- EPS growth
- -20.92%
- 1 year return
- -71.05%
- 3 year return
- -63.22%
- 5 year return
- -55.35%
- 10 year return
- -
Last updated: 2024-12-17
DIVIDENDS
CYAD does not pay dividends or no data was received
VALUATION
Valuation Ratios
Loading...
Valuation Ratios data
| Trailing P/E | 80.00 |
| Price to OCF | - |
| Price to FCF | - |
| Price to EBITDA | - |
| EV to EBITDA | - |
Valuation (Sales/Book Value)
Loading...
Valuation (Sales/Book Value) data
| Price to Sales | - |
| Price to Book | 0.61 |
| EV to Sales | - |
FINANCIALS
Per share
Loading...
Per share data
| Current share count | 22.59M |
| EPS (TTM) | 81.77 |
| FCF per share (TTM) | - |
Income statement
Loading...
Income statement data
| Revenue (TTM) | 0.00 |
| Gross profit (TTM) | 0.00 |
| Operating income (TTM) | -10.00K |
| Net income (TTM) | 148.00K |
| EPS (TTM) | 81.77 |
| EPS (1y forward) | - |
Margins
Loading...
Margins data
| Gross margin (TTM) | - |
| Operating margin (TTM) | - |
| Profit margin (TTM) | - |
Balance Sheet
Loading...
Please create a free account or log in to access this chart
Balance Sheet data
| Cash | 12.45M |
| Net receivables | 0.00 |
| Total current assets | 12.45M |
| Goodwill | 0.00 |
| Intangible assets | 0.00 |
| Property, plant and equipment | 0.00 |
| Total assets | 19.72M |
| Accounts payable | 0.00 |
| Short/Current long term debt | 137.00K |
| Total current liabilities | 137.00K |
| Total liabilities | 274.00K |
| Shareholder's equity | 19.44M |
| Net tangible assets | 0.00 |
Cash flow
Loading...
Please create a free account or log in to access this chart
Cash flow data
| Operating cash flow (TTM) | 0.00 |
| Capital expenditures (TTM) | 0.00 |
| Free cash flow (TTM) | 0.00 |
| Dividends paid (TTM) | 0.00 |
Financial returns
Loading...
Please create a free account or log in to access this chart
Financial returns data
| Return on Equity | 0.76% |
| Return on Assets | 0.75% |
| Return on Invested Capital | 0.76% |
| Cash Return on Invested Capital | - |
STOCK INFORMATION
Downside potential
Loading...
Downside potential data
| CYAD | S&P500 | |
| Current price drop from All-time high | -99.18% | -5.34% |
| Highest price drop | -99.77% | -56.47% |
| Date of highest drop | 23 May 2023 | 9 Mar 2009 |
| Avg drop from high | -68.39% | -11.07% |
| Avg time to new high | 329 days | 12 days |
| Max time to new high | 1450 days | 1805 days |
COMPANY DETAILS
Marketcap
11.84M
Marketcap category
Small-cap
Description
Celyad Oncology SA, a clinical-stage biopharmaceutical company, focuses on the discovery and development of chimeric antigen receptor T (CAR-T) cell therapies for the treatment of cancer. Its lead product candidates include CYAD-101, an allogeneic CAR-T candidate that is in Phase 1b clinical trial for the treatment of metastatic colorectal cancer; CYAD-211, a short hairpin RNA (shRNA)-based allogeneic CAR-T candidate, which is in Phase 1 clinical trial to treat relapsed / refractory multiple myeloma; and CYAD-02, an autologous CAR-T candidate that is in Phase 1 clinical trial for the treatment of relapsed or refractory acute myeloid leukemia and myelodysplastic syndromes. It has licensing agreement with Novartis International AG regarding the United States patents related to allogeneic CAR-T cells; and research and development collaboration, and license agreements with Horizon Discovery Group plc for the use of its shRNA reagents to reduce expression of one or more defined targets. The company was formerly known as Celyad SA and changed its name to Celyad Oncology SA in June 2020. Celyad Oncology SA was founded in 2004 and is headquartered in Mont-Saint-Guibert, Belgium.
Employees
35
Website
Investor relations
-
SEC filings
CEO
Filippo Joseph Petti
Country
USA
City
Mont-Saint-Guibert
Stock type
American depositary share
CCC status
-
Dividend Frequency
-
EVENTS AND PRESENTATIONS
EventsPresentations
Loading...
UNDERSTAND THE BUSINESS
Loading...
COMPANY NEWS
Seeking AlphaPress releases
No items found
iO Charts is a Seeking Alpha partner